Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

Atsushi Tanaka1*, Michio Shimabukuro2, Hiroki Teragawa3, Yosuke Okada4, Toshinari Takamura5, Isao Taguchi6, Shigeru Toyoda7, Hirofumi Tomiyama8, Shinichiro Ueda9, Yukihito Higashi10 and Koichi Node1* on behalf of the EMBLEM Investigators

Abstract

Backgrounds/Aim: Sodium glucose co-transporter 2 inhibitors promote osmotic/natriuretic diuresis and reduce excess fluid volume, and this improves cardiovascular outcomes, including hospitalization for heart failure. We sought to assess the effect of empagliflozin on estimated fluid volumes in patients with type 2 diabetes and cardiovascular disease (CVD).

Methods: The study was a post-hoc analysis of the EMBLEM trial (UMIN000024502), an investigator-initiated, multi-center, placebo-controlled, double-blinded, randomized-controlled trial designed primarily to evaluate the effect of 24 weeks of empagliflozin treatment on vascular endothelial function in patients with type 2 diabetes and established CVD. The analysis compared serial changes between empagliflozin (10 mg once daily, n = 52) and placebo (n = 53) in estimated plasma volume (ePV), calculated by the Straus formula and estimated the extracellular volume (eEV), determined by the body surface area, measured at baseline and 4, 12, and 24 weeks after initiation of treatment. Correlations were examined between the changes from baseline to week 24 in each estimated fluid volume parameter and several clinical variables of interest, including N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration.

Results: In an analysis using mixed-effects models for repeated measures, relative to placebo empagliflozin reduced ePV by −2.23% (95% CI −5.72 to 1.25) at week 4, −8.07% (−12.76 to −3.37) at week 12, and −5.60% (−9.87 to −1.32) at week 24; eEV by −70.3 mL (95% CI −136.8 to −3.8) at week 4, −135.9 mL (−209.6 to −62.3) at week 12, and −144.4 mL (−226.3 to −62.4) at week 24. The effect of empagliflozin on these parameters was mostly consistent across various patient clinical characteristics. The change in log-transformed NT-proBNP was positively correlated with change in ePV (r = 0.351, p = 0.015), but not with change in eEV.

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Introduction**

Previous cardiovascular outcome trials (CVOTs) have demonstrated that sodium glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular and renal outcomes, including hospitalization for heart failure (HHF), in patients with type 2 diabetes and a high risk of cardiovascular events [1]. Furthermore, recent CVOTs have shown that SGLT2 inhibitors reduce the risk of HHF and cardiovascular death in patients with established heart failure (HF) and reduced ejection fraction, regardless of their diabetic status [2], and even in patients who were admitted due to worsening HF [3]. Thus, SGLT2 inhibitors have beneficial effects on cardiovascular outcomes beyond their glucose-lowering action [4], and are now recommended to improve the prognosis of patients with type 2 diabetes and associated risk factors [5, 6]. However, the precise mechanisms of these benefits on cardiovascular disease and their clinical predictors following initiation of SGLT2 inhibitors are not fully understood [7, 8].

SGLT2 inhibitors promote osmotic/natriuretic diuresis and reduce excess plasma and interstitial volumes without affecting effective intravascular circulating volumes [9, 10]. Accordingly, this action of SGLT2 inhibitors appears to contribute substantially to the risk reduction in HHF [11]. In this context, a mediation analysis of data from the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose) trial showed that increases in hematocrit and hemoglobin, indicative of the hemodynamic effect of SGLT2 inhibitors, were the strongest predictors of the reduction in the risk of cardiovascular death [12]. A similar effect was observed in another mediation analysis of data from the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program [13]. Given that the effects of SGLT2 inhibitors on erythropoietic and volume status seem largely to mediate their cardiovascular benefits, some recent clinical studies showed that treatment with SGLT2 inhibitors reduced estimated fluid volume parameters in patients with type 2 diabetes [14] or HF with reduced ejection fraction [15].

In the EMBLEM (Effect of Empagliflozin on Endothelial Function in Cardiovascular High Risk Diabetes Mellitus: Multi-Center Placebo-Controlled Double-Blind Randomized) trial, 24 weeks of empagliflozin treatment did not affect endothelial function in patients with type 2 diabetes and established cardiovascular disease (CVD) [16]. Meanwhile, the erythropoietic parameters increased, and a parameter of estimated plasma volume (ePV) decreased 24 weeks after initiation of empagliflozin, relative to placebo [17]. To extend this initial observation regarding the plasma volume effect of empagliflozin, in the present post-hoc analysis of the EMBLEM trial we sought to further examine the serial changes in estimated fluid volume and their correlations with other clinical variables.

**Methods**

**Study design and participants**

The study was a post-hoc analysis of the EMBLEM trial (UMIN000024502), an investigator-initiated, multicenter, placebo-controlled, double-blinded, randomized-controlled trial undertaken in 16 centers in Japan. The EMBLEM trial was primarily designed to evaluate the effect of 24 weeks of empagliflozin treatment on vascular endothelial function as assessed by the reactive hyperemia index (RHI) in patients with type 2 diabetes and CVD. The details of the design, inclusion/exclusion criteria, and main results have been reported [16–18].

In brief, adults with type 2 diabetes, an HbA1c between 6.0 and 10.0%, and a history of at least one established CVD event (coronary artery disease, stroke, peripheral artery disease, the presence of known coronary artery stenosis (≥50%), or HF except for New York Heart Association classification IV) were included. Key exclusion criteria were a history of CVD, cerebrovascular disease, or coronary revascularization within 3 months before consent. Eligible patients were randomly assigned into either 24 weeks of treatment with empagliflozin (10 mg once daily) or placebo, using the web-based minimization dynamic allocation method, balancing for HbA1c (<7.0 or ≥7.0%), age (<65 or ≥65 years), systolic blood pressure (<140 or ≥140 mmHg), and current smoking habit (smoker of nonsmoker) at the time of screening. Post-randomization follow-up visits were scheduled at weeks 4, 12, and 24.

**Conclusions:** Our data demonstrated that initiation of empagliflozin treatment substantially reduced estimated fluid volume parameters in patients with type 2 diabetes and CVD, and that this effect was maintained for 24 weeks. Given the early beneficial effect of empagliflozin on cardiovascular outcomes seen in similar patient populations, our findings provide an important insight into the key mechanisms underlying the clinical benefit of the drug.

**Trial registration** University Medical Information Network Clinical Trial Registry, number 000024502

**Keywords:** Fluid volume, Empagliflozin, Heart failure, Type 2 diabetes, Cardiovascular disease, N-terminal pro-brain natriuretic peptide
The trial was approved by the institutional review boards of the individual sites. All participants received a detailed explanation of the trial and provided written informed consent.

**Fluid volume estimation**

Estimations of fluid volumes were performed at baseline and at weeks 4, 12, and 24 after randomization using the following formulas and clinical variables. The ePV at baseline was calculated by the Kaplan-Hakim formula [19], and the percentage change in ePV by the Strauss formula [14, 15].

Kaplan-Hakim formula: 
\[
(1 - \text{hematocrit}) \times (a + [b \times \text{bodyweight}(\text{kg})])
\]

\* where \(a = 1530\) in men and 864 in women, and \(b = 41\) in men and 47.9 in women

Strauss formula: 
\[
100 \times \frac{\text{hemoglobin (at baseline)}}{\text{hemoglobin (at visit)}} \times \frac{1 - \text{hematocrit (at visit)}}{1 - \text{hematocrit (at baseline)}} - 100
\]

The extracellular volume (eEV) was estimated by the following formula [15]:

\[
8116.6 \times \left(0.007184 \times \text{height(cm)}^{0.725} \times \text{weight(kg)}^{0.425}\right) - 28.2
\]

**Study endpoint**

The main endpoints in this post-hoc analysis were the between-group differences in the percentage change in ePV and the change in eEV from baseline to weeks 4, 12, and 24. In the empagliflozin arm, the correlations between the changes from baseline to week 24 in each estimated fluid volume and clinical variables of interest were also examined.

**Statistical analysis**

Baseline characteristics are summarized as numbers (percentages) for categorical variables, and as means (with standard deviation) or medians (with interquartile range) for continuous variables, depending on the variable's frequency distribution. Mean changes from baseline in ePV and eEV and their 95% confidence intervals (CI) were estimated by a longitudinal mixed-effects model for repeated measures (MMRM). The effects of empagliflozin vs. placebo on ePV and eEV at weeks 4, 12, and 24 were also assessed in several subgroups according to age, sex, body mass index (BMI), history of HF, diuretic use, and corresponding value at baseline. The proportional change from baseline to week 24 in the N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration was calculated based on its logarithmic scale in the empagliflozin arm. Pearson correlation analyses were performed to examine the associations between changes from baseline to week 24 in each estimated fluid volume parameter and the clinical variables, including log-transformed NT-proBNP concentration.

All statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA). A two-sided significance level of \(P < 0.05\) was used for all assessments, and no adjustment for multiplicity was applied in the analyses.

**Results**

Among 117 patients randomized, 12 were excluded from analysis owing to loss during follow-up or serious protocol deviation. Accordingly, 105 patients were primarily analyzed (empagliflozin \(n = 52\), placebo \(n = 53\)). Detailed baseline characteristics have been reported [16, 17], and were balanced between the treatment groups (Table 1). Briefly, the majority of the subjects were male and had a history of multiple cardiovascular risk factors. Overall, the mean duration of diabetes was 13.3 ± 1.1 years, with a mean glycohemoglobin of 55.9 ± 9 mmol/mol (7.2 ± 0.8%). A total of 42 patients (40.0%) had a history of HF, and 18 patients (17.1%) had been receiving conventional diuretics at baseline.

The baseline values and changes in ePV and eEV from baseline to weeks 4, 12, and 24 are shown in Table 2. The baseline values of ePV and eEV were similar in the treatment groups. Empagliflozin reduced ePV and eEV compared to placebo from baseline to week 4 (ePV, non-adjusted mean group-difference = 1.98% [95% CI = 5.54 to 1.57]; eEV = 57.2 mL [95% CI = 124.8 to 10.4]), to week 12 (ePV, −7.85% [95% CI = 12.65 to −3.05]; eEV = 143.4 mL [95% CI = 206.5 to −80.3]), and to week 24 (ePV, −5.33% [95% CI = 9.84 to −1.22]; eEV = 145.5 mL [95% CI = 228.4 to −62.7]). In the adjusted analysis using the MMRM model, relative to placebo empagliflozin significantly reduced ePV by −8.07% (95% CI = 12.76 to −3.37) at week 12 and by −5.60% (95% CI = 9.87 to −1.32) at week 24; eEV by −70.3 mL (95% CI = 136.8 to −3.8) at week 4, −135.9 mL (95% CI = 209.6 to −62.3) at week 12, and by −144.4 mL (95% CI = 226.3 to −62.4) at week 24 (Fig. 1).

The effects of empagliflozin on ePV (Fig. 2) and eEV (Fig. 3) in the total subjects were almost consistent across the different patient subgroups at weeks 4, 12 and 24. Specifically, relative to placebo, empagliflozin reduced those parameters at weeks 12 and 24, regardless of BMI, history of HF, diuretic use, and the corresponding estimated fluid volume at baseline. All P values for interaction, except according to β-blocker use at baseline for eEV at weeks 4 and 12, were > 0.05.
Twenty-four weeks of empagliflozin treatment did not change the NT-proBNP concentration (geometric mean 71.3 pg/mL [95% CI 48.7 to 104.4] at baseline and 66.1 pg/mL [95% CI 46.3 to 94.2] at week 24, proportional change 0.995 [95% CI 0.833 to 1.189]). In the continuous analyses, the change from baseline to week 24 in log-transformed NT-proBNP concentration was positively correlated with the corresponding change in ePV, but not with that in eEV (Fig. 4).

Detailed changes in clinical parameters, including body weight, hematocrit, and hemoglobin, from baseline to weeks 4, 12, and 24 are shown in Additional file 1, while changes in other clinical data from baseline to week 24 have been reported previously [16, 17]. There were weak correlations between changes from baseline to week 24 in ePV and glycohemoglobin and estimated glomerular filtration rate, and the change in eEV was correlated with changes in systolic blood pressure and BMI (Table 3). No significant correlations between changes from baseline to week 24 in either of the estimated fluid volumes (ePV and eEV) and other measured parameters were observed.

**Discussion**

In this post-hoc analysis of the EMBLEM trial, the magnitudes of the reductions of the estimated fluid volumes from baseline to 4, 12, and 24 weeks after initiation of empagliflozin 10 mg once daily, relative to placebo, were robust in patients with type 2 diabetes and CVD. This effect was mostly consistent across patient medical backgrounds. Our findings suggest that an early and sustained effect of empagliflozin on volume-related markers is a key mechanism underlying the clinical benefit of the drug.

SGLT2 inhibitors possess pleiotropic hemodynamic and metabolic actions beyond their glucose-lowering action, causing direct and indirect effects for cardiovascular and renal protection [7]. However, the CVOTs were not primarily designed to determine the mechanisms that might mediate these prognostic relationships, and the mechanisms underlying the clinical benefits of SGLT2 inhibitors remain uncertain. Such benefits are unlikely to be associated with their glucose-lowering action or the diabetic status of patients [20–22]. Interestingly, two recent mediation analyses of data obtained from CVOTs (the EMPA-REG OUTCOME trial and the CANVAS program) suggested that changes in markers of erythropoiesis and volume status were the most important mediators of the decreases in the risk of HHF and cardiovascular death [12, 13]. Thus, this approach revealed possible determinants of the probability of clinical benefit during treatment with SGLT2 inhibitors, and brought much attention to such secondary effects of the drugs.

SGLT2 inhibitors are known to promote osmotic/natriuretic diuresis and to reduce excess fluid volumes without affecting effective intravascular circulating volume, presumably underlying the risk reduction in HHF [9–11]. To estimate changes in fluid volume status during SGLT2 inhibitor therapy, previous studies examined the effects of dapagliflozin or canagliflozin on Strauss formula-based ePV, an established prognostic marker in patients with HF [19, 23]. These analyses showed consistent decreases in a broad range of patients with type 2 diabetes, irrespective of their HF status [14, 24]. More recently, 12 weeks of empagliflozin reduced both ePV and eEV, estimated by the body surface area, in patients

**Table 1** Baseline characteristics of the included patients

|                          | Empagliflozin (n = 52) | Placebo (n = 53) |
|--------------------------|------------------------|-----------------|
| Age, yrs                 | 65.4 ± 11.1            | 64.1 ± 9.9      |
| Males                    | 36 (69.2)              | 36 (67.9)       |
| Systolic blood pressure, mm Hg | 132.8 ± 15.2           | 133.0 ± 14.5    |
| Diastolic blood pressure, mm Hg | 76.4 ± 11.5            | 74.9 ± 9.5      |
| Body mass index, kg/m²   | 26.2 ± 5.1             | 26.9 ± 5.5      |
| Hemoglobin, g/dL         | 140.0 ± 1.6            | 137.1 ± 1.5     |
| Hematocrit, %            | 41.6 ± 4.6             | 41.3 ± 4.2      |
| Uric acid, mg/dL         | 5.7 ± 1.4              | 5.3 ± 1.1       |
| Diabetes duration, yrs   | 13.6 ± 13.2            | 13.0 ± 8.3      |
| Fasting plasma glucose, mg/dL | 141.4 ± 25.0          | 146.4 ± 34.8    |
| Glycohemoglobin, % (mmol/mol) | 7.2 ± 0.8 (55 ± 9)    | 7.2 ± 0.9 (55 ± 10) |
| eGFR, mL/min/1.73 m²     | 67.0 ± 12.5            | 69.2 ± 13.9     |
| UACR, mg/g-Cre           | 32.0 (8.0 to 65.0)     | 15.3 (7.5 to 41.5) |
| NT-proBNP, pg/mL         | 63.0 (31.0 to 180.0)   | 80.5 (20.0 to 122.0) |
| High-sensitivity troponin I, pg/mL | 3.2 (2.3 to 6.3) | 4.1 (2.2 to 8.1) |
| Past medical history     |                        |                 |
| Hypertension             | 41 (78.8)              | 36 (67.9)       |
| Dyslipidemia             | 39 (75.0)              | 38 (71.7)       |
| Heart failure            | 23 (44.2)              | 19 (35.8)       |
| Myocardial infarction    | 12 (23.1)              | 13 (24.5)       |
| Treatment                |                        |                 |
| Metformin                | 25 (48.1)              | 28 (52.8)       |
| Thiazolidinedione        | 12 (23.1)              | 13 (24.5)       |
| DPP-4 inhibitor          | 37 (71.2)              | 36 (67.9)       |
| ACE inhibitor or ARB     | 31 (59.6)              | 38 (71.7)       |
| Beta-blocker             | 19 (36.5)              | 19 (35.8)       |
| MRA                      | 9 (17.3)               | 5 (9.4)         |
| Diuretic                 | 8 (15.4)               | 10 (18.9)       |

Data are expressed as n (%), mean ± SD or median (interquartile)

ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, DPP-4 dipeptidyl peptidase-4, eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide, UACR urinary albumin-creatinine ratio
with HF and reduced ejection fraction, regardless of diabetic status [15]. In the present analysis, we also examined changes in ePV and eEV following initiation of empagliflozin treatment through 24 weeks in order to extend previous findings to patients with type 2 diabetes at high risk of CVD, specifically similar to the previous CVOTs with SGLT2 inhibitors, and to explore mechanisms underlying the early benefit of SGLT2 inhibitors in that patient population.

In the initial results of the EMBLEM trial, 24 weeks of empagliflozin did not affect endothelial function as assessed by RHI in patients with type 2 diabetes and CVD [16, 17], suggesting that improvement of vascular function was unlikely to have been responsible for the early clinical benefits observed in the CVOTs with SGLT2 inhibitors. In contrast, the present analysis demonstrated reductions of the estimated fluid volumes at week 4 following initiation of empagliflozin that were

### Table 2 Changes in estimated fluid volume status at weeks 4, 12, and 24

|                          | Empagliflozin | Placebo | Group difference (95% CI) |
|--------------------------|---------------|---------|---------------------------|
| **ePV**                  |               |         |                           |
| Baseline (n)             | 51            | 53      | -63 (−222 to 96)          |
| Change from baseline to 4 weeks, % | -1.19±7.06   | 0.79±9.59 | -1.98 (−5.54 to 1.57) |
| Change from baseline to 12 weeks, % | -7.42±9.50    | 0.43±13.35 | -7.85 (−12.65 to −3.05) |
| Change from baseline to 24 weeks, % | -6.66±12.57  | -1.13±8.98 | -5.53 (−9.84 to −1.22) |
| Baseline, mL             | 52            | 53      | -228 (−873 to 416)        |
| Change from baseline to 4 weeks, mL | -32.4±172.5 | 24.9±153.6 | -57.2 (−124.8 to 10.4) |
| Change from baseline to 12 weeks, mL | -131.2±139.7 | 12.3±166.5 | -143.4 (−206.5 to −80.3) |
| Change from baseline to 24 weeks, mL | -168.3±202.2 | -22.8±218.8 | -145.5 (−228.4 to −62.7) |

Data are expressed as mean ± SD

CI confidence interval, eEV estimated extracellular volume, ePV estimated plasma volume

* ePV at baseline was calculated by the Kaplan-Hakim formula

---

**Fig. 1** Effect of empagliflozin on estimated fluid volume status through week 24. eEV estimated extracellular volume, eGD estimated group difference, ePV estimated plasma volume
### Fig. 2
Subgroup analyses of change in ePV through week 24. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, CI confidence interval, DPP-4 dipeptidyl peptidase-4, eEV estimated extracellular volume, eGFR estimated glomerular filtration rate, ePV estimated plasma volume, HF heart failure, SBP systolic blood pressure, UACR urinary albumin-creatinine ratio.

| Week 4 | Group difference (95% CI) | P value for interaction | Week 13 | Group difference (95% CI) | P value for interaction | Week 24 | Group difference (95% CI) | P value for interaction |
|--------|---------------------------|-------------------------|--------|---------------------------|-------------------------|--------|---------------------------|-------------------------|
| Overall | -0.96 [-1.08, -0.84]      | 0.277                   |        |                           |                         |        |                           |                         |
| Age  |< median age of 67 |           | -0.15 [-0.26, 0.00]        | 0.141                  | -0.56 [-0.82, -0.29] | 0.071      | -0.53 [-0.84, -0.22] | 0.277                   |
|       | median age of 67  |           | 0.25 [-0.06, 0.56]         | 0.127                  | 0.62 [-0.06, 0.25]    | 0.067      | 5.43 [-1.27, 0.56]    | 0.095                   |
| Sex   | Male                   | -2.23 [-5.70, 1.25]    | 0.277 | -5.44 [-8.41, -2.47] | 0.070                  | -5.65 [-8.51, -0.28] | 0.007      | -5.64 [-8.51, -0.28] | 0.007                   |
|       | Female                 | -2.51 [-6.00, 1.08]    | 0.067 | -5.57 [-8.51, -2.63] | 0.005                  | -5.64 [-8.51, -0.28] | 0.007      | -5.64 [-8.51, -0.28] | 0.007                   |
| BMI   |< median of 25.5 |           | -2.18 [-5.26, 1.90]        | 0.326                  | -2.47 [-5.40, -0.54] | 0.059      | -2.46 [-5.40, -0.54] | 0.059                   |
|       | median of 25.5       |           | 0.15 [-0.70, 0.99]         | 0.616                  | -0.16 [-0.67, 0.35]  | 0.603      | -0.16 [-0.67, 0.35]  | 0.603                   |
| Age   |< median age of 67 |           | -0.96 [-1.62, -0.30]       | 0.746                  | -1.73 [-2.74, -0.71] | 0.005      | -1.66 [-2.66, -0.66] | 0.005                   |
|       | median age of 67  |           | 0.20 [-0.52, 0.92]         | 0.540                  | 0.26 [-0.35, 0.85]   | 0.483      | 0.26 [-0.35, 0.85]   | 0.483                   |
| Sex   | Male                   | -1.71 [-4.07, 0.65]    | 0.277 | -2.65 [-5.00, -0.31] | 0.029                  | -2.56 [-5.00, -0.12] | 0.039      | -2.56 [-5.00, -0.12] | 0.039                   |
|       | Female                 | -2.65 [-5.00, -0.31]   | 0.228 | -4.54 [-6.90, -2.18] | 0.003                  | -4.54 [-6.90, -2.18] | 0.003      | -4.54 [-6.90, -2.18] | 0.003                   |
| BMI   |< median of 25.5 |           | -2.86 [-5.42, 0.70]        | 0.326                  | -5.55 [-7.90, -3.21] | 0.005      | -5.43 [-7.79, -3.07] | 0.005                   |
|       | median of 25.5       |           | 0.13 [-1.62, 1.88]         | 0.896                  | 0.26 [-1.51, 1.99]   | 0.686      | 0.26 [-1.51, 1.99]   | 0.686                   |
| ACE   | inhibitor or ARB use at baseline |           | -0.63 [-1.44, 0.19]        | 0.160                  | -0.30 [-0.93, 0.34]  | 0.509      | -0.30 [-0.93, 0.34]  | 0.509                   |
|       | yes                   | 0.91 [0.41, 2.41]     | 0.391 | -0.71 [-2.21, 0.80] | 0.420                  | -0.43 [-1.91, 0.05] | 0.071      | -0.43 [-1.91, 0.05] | 0.071                   |
| Diabetic use at baseline |           | -1.17 [-4.07, 1.73]       | 0.540                  | -1.62 [-4.01, 0.76]  | 0.243                  | -1.62 [-4.01, 0.76] | 0.243      | -1.62 [-4.01, 0.76] | 0.243                   |
|       | yes                   | -0.19 [-0.65, 0.36]    | 0.563 | -0.71 [-3.24, 0.84] | 0.500                  | -0.67 [-3.24, 0.84] | 0.500      | -0.67 [-3.24, 0.84] | 0.500                   |
| Metformin use at baseline |           | -1.05 [-2.03, 0.00]       | 0.091                  | -0.65 [-2.10, 1.77]  | 0.630                  | -0.17 [-2.10, 1.77] | 0.820      | -0.17 [-2.10, 1.77] | 0.820                   |
| Thiazolidinediones use at baseline |           | -2.16 [-4.34, 0.08]       | 0.093                  | -1.73 [-3.43, 0.46]  | 0.197                  | -1.53 [-3.23, 0.15] | 0.089      | -1.53 [-3.23, 0.15] | 0.089                   |
| DPP-4 inhibitor use at baseline |           | -2.36 [-4.22, 0.50]       | 0.075                  | -1.58 [-3.26, -0.10] | 0.054                  | -1.35 [-3.03, -0.28] | 0.015      | -1.35 [-3.03, -0.28] | 0.015                   |
| eEV at baseline |< median of 2495 |           | -2.06 [-4.67, 0.57]        | 0.336                  | -3.53 [-6.13, -0.93] | 0.019      | -3.68 [-6.28, -0.12] | 0.047                   |
|       | median of 2495 |           | -0.25 [-1.71, 1.23]        | 0.720                  | -0.20 [-1.74, 1.33]  | 0.862      | -0.20 [-1.74, 1.33] | 0.862                   |

### Fig. 3
Subgroup analyses of change in eEV through week 24. eEV estimated extracellular volume. Others see Fig. 2.
maintained until 24 weeks. Notably, in the EMPA-REG OUTCOME trial, the risk reduction in HHF was apparent immediately after initiation of empagliflozin, and was also consistent across subgroups stratified by a variety of clinical backgrounds [25]. These findings suggest that the early hemodynamic action of SGLT2 inhibitors and resulting regulation of fluid volume are major factors that contribute to the beneficial impact on cardiovascular events in patients with type 2 diabetes and a high risk of CVD, especially for those with HHF [26, 27].

In the present analysis, a reduction in ePV relative to placebo was apparent at week 12 following initiation of empagliflozin. This is likely due to the previous observation that the erythropoiesis and relevant variables (hematocrit and hemoglobin) that were incorporated into the Strauss formula gradually increase after 4 weeks of SGLT2 inhibitor treatment, and continue over time [28–30]. On the other hand, the effect on eEV, which was based on body surface area, developed soon after initiation of empagliflozin and was also sustained until 24 weeks, regardless of patient medical backgrounds. This finding would be consistent with the sustained body weight loss that has been reported after initiation of SGLT2 inhibitors [28], although the diuretic effect and loss of extracellular volume resulting from SGLT2 inhibition appears to be transient [31, 32]. Therefore, the variations in estimated fluid volumes reflected changes in relevant clinical variables following initiation of empagliflozin treatment.

Regarding the effects of SGLT2 inhibition on erythropoiesis, in 2019 Sano et al. [33] proposed a possible mechanism to explain the increase in hematocrit associated with SGLT2 inhibition. This involved an improvement in the hypoxic microenvironment of the renal tubular interstitium, with SGLT2 inhibition promoting phenotypic reverse-transformation of non-functional...
myofibroblasts to erythropoietin-producing fibroblasts, thereby stimulating erythropoietin production and subsequent erythropoiesis [33]. Recently, Mazzer et al. [34] reported that SGLT2 inhibition with empagliflozin in patients with T2D and coronary artery disease increased early erythropoietin levels. These authors also proposed several SGLT2-associated renal mechanisms that included increased β-hydroxybutyrate levels and expression of hypoxia-inducible factors (HIFs) [34]. Furthermore, the increase in erythropoiesis may be explained by SGLT2 inhibitor-mediated activation of sirtuin-1 signaling and subsequent regulation of imbalances in HIF-1α and HIF-2α [35]. Taken together these findings indicate that increased erythropoiesis associated with SGLT2 inhibition appears to reflect favorable intrarenal responses, rather than simple hemoconcentration through loss of intravascular fluid volume. This possibility suggests that this action, itself, is likely to be the key mediator of the cardiorenal protective effect of SGLT2 inhibitors.

The present study also showed that change in the log-transformed NT-proBNP concentration was weakly but significantly correlated with change in ePV, while no correlation with eEV was observed. Several studies in patients who received HF treatment have also demonstrated that changes in ePV were correlated with those in natriuretic peptide concentration [36]. Although the reason for the difference observed between ePV and eEV is unclear, ePV is a more suitable marker of left ventricular wall stress status, suggesting an easy-to-obtain indicator of cardiac workload. Given the consistent reduction of ePV after initiation of SGLT2 inhibitors, these findings also offer an explanation for the cardiovascular benefits seen in the CVOTs with SGLT2 inhibitors.

Limitations of the present study include that this was a post-hoc analysis, that a rather small number of patients were recruited, and that the estimations of fluid volumes were limited to 4, 12, and 24 weeks after the start of treatment. Given the number of analyses performed our data cannot exclude susceptibility to multiplicity and the presence of type I statistical errors. Further studies and large-scale observations are therefore warranted to investigate whether SGLT2 inhibitor-induced reduction in fluid volumes is predictive of long-term clinical benefit in patients with variable clinical characteristics. Most importantly, no direct measures of fluid volume were made in the present study. Both ePV and eEV were influenced by the changes in the variables incorporated in their formulas, although several studies have demonstrated reasonable correlations between estimated and measured (actual) fluid volumes [14, 36]. In particular, given the transient diuretic effect of SGLT2 inhibitor described above, it is possible that estimation of plasma volume status using the Strauss formula might be substantially influenced substantially by SGLT2 inhibitor-induced erythropoiesis. We are therefore unable to exclude the possibility that the present estimated changes in volume status were partially the result of actual changes in plasma volume status. It is necessary to measure SGLT2 inhibitor-induced changes in body composition and fluid status directly using the bioimpedance method [32, 37].

In conclusion, our data demonstrate that empagliflozin substantially reduced the estimated fluid volume parameters in patients with type 2 diabetes and CVD, and that this effect was maintained for 24 weeks. Given the early beneficial effect of empagliflozin on cardiovascular outcomes seen in similar patient populations, our findings suggest an important insight into key mechanisms underlying the clinical benefit of the drug.

**Abbreviations**
BMI: Body mass index; CI: Confidence interval; CVD: Cardiovascular disease; CVOT: Cardiovascular outcome trial; eEV: Estimated extracellular volume; ePV: Estimated plasma volume; HF: Heart failure; HHF: Hospitalization for heart failure; HIF: Hypoxia-inducible factor; MMRM: Mixed-effects models for repeated measures; NT-proBNP: N-terminal pro-brain natriuretic peptide; RHI: Reactive hyperemia index; SGLT2: Sodium glucose co-transporter 2.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12933-021-01295-6.

**Additional file 1.** Changes in clinical parameters at weeks 4, 12, and 24.

**Acknowledgements**
The authors thank all the investigators, board members, coordinators, CRO (DOT WORLD CO., LTD. Tokyo, Japan) and patients who participated in the EMBLEM trial.

**Authors’ contributions**
AT participated in the study design, operations, analysis and interpretation of data, and drafted the paper. MS, HirokT, YO, TT, ST, HirofT, SU, and YH participated in the study design, operations, and collection and interpretation of data. KN was a principal investigator of the EMBLEM trial and reviewed the manuscript critically. All authors approved the final version of the manuscript and take full responsibility for its content.

**Funding**
The work was funded by Boehringer Ingelheim and Eli Lilly and Company. The funder of the trial had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

**Availability of data and materials**
The datasets analyzed during the current study are available from the corresponding author on reasonable request (tanakaa2@cc.saga-u.ac.jp).
Declarations

Ethics approval and consent to participate
The ethical committees of the participating institutions approved the study protocol. Written informed consent for participation in the study was obtained from all the subjects.

Consent for publication
All authors have read and approved the submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language. If the manuscript is accepted, we approve it for publication in Cardiovascular Diabetology.

Competing interests
AT received honoraria from Boehringer Ingelheim, and research funding from GlaxoSmithKline. MS received honorarium and endowed chair from Boehringer Ingelheim. Hiroki T received lecture fees from Bayer, Boehringer Ingelheim, Daichi Sankyo, Kowa, and Sanwa Kagaku Kenkyusho; and research funds from Kowa and Mitsubishi Tanabe. TT received honoraria from MSD, AstaZeneca, Mitsubishi Tanabe; research funding from Otsuka, AstraZeneca, Astellas, and Novo Nordisk. Hori T received research funding from Omron Health Care, Asahi Calpis Wellness, and Teijin. SU received research grants from Bristol-Myers Squibb and Kowa; and non-purpose research grants from Bristol-Myers Squibb, Chugai, MSD, Pfizer, and Takeda; and lecture fees from Boehringer Ingelheim and MSD. YH received consulting fees from Mitsubishi Tanabe related to this study, as well as honoraria and grants from Teijin, Boehringer Ingelheim, MSD, Sanofi, AstraZeneca, Kyowa Hakko Kirin, Takeda, Astellas, Daichi Sankyo, Mochida, Nihon Kohden, Shionogi, Nippon Sigmax, Sanwa Kagaku Kenkyusho, Unex, and Kao, hono-
raria from Radiometer, Omron, Sumitomo Daiinippon, Otsuka, Torii, Kowa, Fuji-
yakuhiin, Amgen, Nippon Shinyaku, Ibar, Bella, Li, Lily, and Ono. KN received research grants from Asahi Kasei, Astellas, Bayer, Boehringer Ingelheim, Mitsubishi Tanabe, Teijin, and Terumo; scholarships from Astellas, Bayer, Bristol-
Myers Squibb, Daichi Sankyo, Daichi Sankyo Healthcare, Takeda, and Teijin; and personal fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daichi Sankyo Healthcare, Eli Lilly, Kowa, Mitsubishi Tanabe, MSD, Novartis, Ono, Takeda, and Teijin. All other authors declare no competing interests.

Author details
1 Department of Cardiovascular Medicine, Saga University, 5-5-1 Nabeshima, Saga 849-8501, Japan. 2 Department of Diabetes, Endocrinology, and Metaboli-
sm, Fukushima Medical University, Fukushima, Japan. 3 Department of Cardio-
vascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan. 4 First Department of Internal Medicine, School of Medicine, University of Occupational and Envi-
ronmental Health, Japan, Kitakyusu, Japan. 5 Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. 6 Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan. 7 Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine, Mibu, Japan. 8 Department of Cardiology, Tokyo Medical University, Tokyo, Japan. 9 Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan. 10 Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Received: 18 March 2021   Accepted: 29 April 2021
Published online: 28 June 2021

References
1. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England). 2019;393(10166):31–9.
2. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueck-
mann M, Ofstad AP, Piaf E, Jamali W, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396(10254):819–29.
3. Bhatt DL, Szeare M, Steg PG, Cannon CP, Leifer TA, Maguire DK, Lewis J, Riddle MC, Voors AA, Metra M, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28.
4. Zelniker TA, Braunwald E. Clinical benefit of cardiological effects of sodium-
glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):435–47.
5. Pharmacologic Approaches to Glycemic Treatment. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S11–S124.
6. Consentino F, Grant PJ, Aboyans V, Bailey C, Cierullo A, Delgado V, Federici M, Filippatos G, Groebbe DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collabo-
ration with the EASD. Eur Heart J. 2020;41(2):355–323.
7. Zelniker TA, Braunwald E. Mechanisms of cardiological effects of sodium-
glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422–34.
8. Tanaka A, Noda K. How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition? Cardiovasc Diabetol. 2020;19(1):206.
9. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–17.
10. Lytvyn Y, Bjornstad P, Udelø JA, Lovshin JA, Cherney DZI. Sodium Glycose Cotransporter-2 Inhibition in Heart Failure: Potential Mecha-
nisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017;136(17):1643–58.
11. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20(3):479–87.
12. Inuzuchi SE, Zinnin B, Fitchen D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohnhausen E, Johansen OE, George JT, et al. How Does empa-
gliflozin reduce cardiovascular mortality? Insights from a mediation anal-
ysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018;41(2):356–63.
13. Januzzi JL Jr, Xu J, Li J, Shaw W, Oh R, Pfeifer M, Butler J, Sattar N, Mahaffey
K, Neal B, et al. Effects of canagliflozin on amino-terminal pro-b-type natriuretic peptide: implications for cardiovascular risk reduction. J Am Coll Cardiol. 2020;76(18):2076–85.
14. Dekkers CCJ, Sjostrom CD, Greasley PJ, Cin B, Boulton DW, Heerspink HIL. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(12):2667–73.
15. Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Kaber L, Gustafsson F, Faber J, Malik ME, Fosbel EL, et al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glom-
nerular filtration rate in patients with heart failure (Empire HF Renal): a pre-
specified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(9):106–16.
16. Tanaka A, Shimabuku M, Machii N, Teragawa H, Okada Y, Shima KR, Takamura T, Taguchi I, Hisauchi I, Toyoda S, et al. Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: results from the multicenter, randomized, placebo-controlled double-blind EMBLEM trial. Diabetes Care. 2019;42(10):e159–61.
17. Tanaka A, Shimabuku M, Machii N, Teragawa H, Okada Y, Shima KR, Takamura T, Taguchi I, Hisauchi I, Toyoda S, et al. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus. Multi-center placebo-controlled double-blind randomized trial. J Diabetes Invest. 2020;11(6):1551–63.
18. Tanaka A, Shimabuku M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, et al. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol. 2017;16(1):48.
19. Fudim M, Miller WL. Calculated estimates of plasma volume in patients with chronic heart failure—comparison with measured volumes. J Cardiac Fail. 2018;24(9):553–60.
20. Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1):98.
21. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353–68.
22. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26.
23. Duarte K, Monnez JM, Albuisson E, Pitt B, Zannad F, Rossignol P. Prognostic value of estimated plasma volume in heart failure. JACC. Heart failure. 2015;3(1):886–93.
24. Tanaka A, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Tomiyama H, Sata M, Ueda S, Oyama JI, Kitakaze M, et al. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE). ESC heart failure. 2020;7(4):1585–94.
25. Fitchett D, Zinman B, Wanner C, Hantel S, Salsali A, Johannsen OE, Woerle HJ, Broedl UC, Inzucchi SE. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOMES trial. Eur Heart J. 2016;37(19):1526–34.
26. Tanaka A, Node K. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. J Cardiol. 2017;69(3):501–7.
27. Tanaka A, Node K. Fluid volume regulation in patients with heart failure. Lancet Diabetes Endocrinol. 2021;9(5):256–7.
28. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin: a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–62.
29. Ferrannini E, Baldi S, Frascerra S, Astariaga B, Barsotti E, Clerico A, Musceti E. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40(6):771–6.
30. Aberle J, Menzen M, Schmid SM, Tekamp C, Jaeckel E, Rohwedder K, Scheerer MF, Xu J, Tang W, Birkenfeld AL. Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes. Sci Rep. 2020;10(1):22396.